Faheem Hasnain ups cash haul to $330M for a fledgling biotech that is moving ‘at light speed’
Just six months ago, Faheem Hasnain rolled out his latest biotech venture with a $100 million mega-round for seed money. Today, he’s adding $230 million more for Gossamer Bio from a global syndicate of heavyweight investors that is betting big that the ex-Receptos chief and his team can birth a major new company virtually overnight by biotech standards, with a pipeline that already includes 4 drugs, more therapies coming and an employee roster slated to hit 100 by the end of this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
